(cml), in which the bcr-abl fusion gene (the product of a reciprocal translocation between chromosome 9 and chromosome 22) is present in >95% of cases and produces hyperactivated abl-driven protein signaling. these medications specifically inhibit the ableson tyrosine kinase (abl) protein and are thus a prime example of "rational drug design" based on knowledge of disease pathophysiology. the foundationone cdx report produced by foundation medicine, which looks at genes in individual patients' tumor biopsies and recommends specific drugs high mutation burden is indicative of response to immunotherapy, and also specific patterns of mutations have been associated with previous exposure to cytotoxic cancer drugs. population screening